Cannvas MedTech (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to announce it is partnering with Pancreatic Cancer Canada to provide free educational content to patients and caregivers across the country curious to learn whether cannabis can be a beneficial part of their treatment.

“Access to physician-backed education around cannabis is crucial for everyone, particularly for patients and caregivers struggling with a disease as frightening as pancreatic cancer,” says Shawn Moniz, Chief Executive Officer of Cannvas MedTech Inc. “Pancreatic Cancer Canada will be able to offer their community an online portal, powered by our Cannvas.Me platform, to share knowledge and experiences about the benefits of using medical cannabis as an alternative health care option, and through this partnership Cannvas will have access to greater research and data to better serve our users going forward.”


Pancreatic Cancer Canada and Cannvas worked together to launch the first round of content on Cannvas.Me to mark National Pancreatic Cancer Awareness Month in November. It remains online at Cannvas.Me/PancreaticCancer as part of the Cannvas Health Advocacy Team (CHAT) initiative, designed to delve deeper into health conditions and provide clarity on lesser-known medical ailments affecting large swaths of the population.

The two organizations also plan to collaborate and share resources to create original content contextualized to fit the needs of pancreatic cancer patients and their caregivers. Additional content will be created regularly by both organizations based on community feedback received by Pancreatic Cancer Canada.

“As a national organization dedicated to pancreatic cancer, we play an integral role in ensuring that the patient community and public at large have timely and up-to-date information. Given the very fast progression of this disease for the majority of people who receive a diagnosis, managing symptoms and accessing tools for living as well as they possibly can is paramount.  We are excited to work with Cannvas MedTech to bring the Cannvas.Me platform to our community and their healthcare teams as an unbiased, science-based tool for determining if cannabis might a viable option for them.” Michelle Capobianco, Executive Director, Pancreatic Cancer Canada.

Cannvas will enable the wellness and education of the Pancreatic Cancer Canada community through access to its free and unbiased cannabis education resource, Cannvas.Me. The platform features physician-backed content overseen by certified educators for all audiences wishing to learn about whether the benefits of medical or therapeutic cannabis fit their lifestyle.

Pancreatic cancer patients and caregivers will be able to access physician testimonials, patient stories, research papers and educational courses about the potential benefits of medical cannabis. Those interested in enriching their knowledge on the subject will be able to continue their cannabis education with Cannvas through a variety of targeted courses and articles.

“My wife’s family struggled with the loss of her mother to pancreatic cancer and it’s an overwhelming disease to deal with in a very short period of time, creating a real sense of urgency around the comfort and wellness of the patient,” said Steve Loutskou, Chief Operating Officer, Global Markets for Cannvas MedTech Inc. “We are looking forward to helping create an outlet of distribution for education around the potential benefits medical cannabis can provide pancreatic cancer patients, from pain relief to increased appetite.”

Cannvas was also the main sponsor of the third annual Lip Sync Battles Cancer fundraiser in support of Pancreatic Cancer Canada that took place in Montreal on Saturday, November 24 at the Phi Centre, a meticulously restored heritage building located at 407 Rue Saint-Pierre in Old Montreal. Hosted by Michael Musi, a Montreal-born-and-raised actor who can be found playing Terence on the hit CBC show “Kim’s Convenience”, the fundraiser featured local talent raising awareness and an amazing $19,000 for this cancer.

About Pancreatic Cancer Canada
Pancreatic Cancer Canada is the only national organization devoted to fighting pancreatic cancer through research, awareness, education and advocacy. Our goals are to improve overall patient survival rates, change the outcomes and create a brighter future for those affected by pancreatic cancer. For more information about the Pancreatic Cancer Canada Foundation: PancreaticCancerCanada.ca

About Lip Sync Battles
Lip Sync Battles Cancer was born three years ago when co-founders Marianne Musi and Vince Colletti decided to have a get-together with friends and host a Lip Sync Battle. The idea flourished into a fundraising event where all proceeds go to Pancreatic Cancer Canada. Michael and Marianne Musi are extremely passionate about raising funds for pancreatic cancer since it took their 52-year-old mother a little over five years ago. Event Details: https://www.facebook.com/events/393570737841946/

About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: www.cannvasmedtech.com, Media Inquiries: media@cannvasmedtech.com; Investor Relations: ir@cannvasmedtech.com, 1-800-489-0116

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less